Molecular Profile Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name	BRAF fusion
Gene Variant Detail	BRAF fusion (unknown)
Relevant Treatment Approaches

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 14 of 14 entries

Molecular Profile	Indication/Tumor Type	Response Type	Relevant Treatment Approaches	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
BRAF fusion	childhood low-grade glioma	sensitive		Tovorafenib	FDA approved	Actionable	In a Phase II trial (FIREFLY-1) that supported FDA approval, Ojemda (tovorafenib) was well tolerated and resulted in an overall response rate (ORR) per RAPNO criteria of 51% (39/76, 28 partial and 11 minor responses), clinical benefit rate (CBR) of 82% (62/76), and median duration of response of 13.8 mo in pediatric patients with low-grade glioma harboring BRAF fusions, rearrangements, or BRAF V600 mutations, with an ORR of 52% (33/64) in patients harboring BRAF fusions (PMID: 37978284; NCT04775485).	detail... 37978284
BRAF fusion	pilocytic astrocytoma	not applicable		N/A	Guideline	Diagnostic	BRAF fusions aid in the diagnosis of pilocytic astrocytoma (NCCN.org).	detail...
BRAF fusion	pilocytic astrocytoma	not applicable		N/A	Guideline	Prognostic	BRAF fusions are associated with indolent disease in patients with pilocytic astrocytoma (NCCN.org).	detail...
BRAF fusion	pilocytic astrocytoma	sensitive		Selumetinib	Guideline	Actionable	Koselugo (selumetinib) is included in guidelines for patients with recurrent or progressive pilocytic astrocytoma harboring a BRAF fusion (NCCN.org).	detail...
BRAF fusion	skin melanoma	sensitive		Trametinib	Guideline	Actionable	Mekinist (trametinib) is included in guidelines as second-line therapy for metastatic or unresectable cutaneous melanoma patients with BRAF fusions (NCCN.org).	detail...
BRAF fusion	Advanced Solid Tumor	predicted - sensitive		PLX8394	Phase Ib/II	Actionable	In a Phase I/II trial, PLX8394 treatment resulted in stable disease in 46% of patients with advanced solid tumors harboring BRAF fusions and a complete response with a duration of response of at least 51.8 months in a patient with melanoma harboring AGK-BRAF (J Clin Oncol 41, 2023 (suppl 16; abstr 3006); NCT02428712).	detail...
BRAF fusion	Advanced Solid Tumor	predicted - sensitive		Belvarafenib + Cobimetinib	Phase I	Actionable	In a Phase I trial (HM-RAFI-103), Belvarafenib (HM95573) and Cotellic (cobimetinib) combination therapy demonstrated preliminary activity in patients with advanced solid tumors harboring BRAF fusions, resulting in an objective response rate of 60% (9/15, all partial responses), a disease control rate of 93.3% (14/15), with a median progression-free survival of 13.7 months, and a median duration of response of 12 months (Ann Oncol 34 (2023): S465; NCT03284502).	detail...
BRAF fusion	prostate cancer	no benefit		Trametinib	Case Reports/Case Series	Actionable	In a Phase II trial (NCI-MATCH), Mekinist (trametinib) treatment did not demonstrate clinical activity in patients with advanced solid tumors or lymphoma harboring BRAF fusion or non-V600 mutations, resulted in progressive disease in a patient with prostate cancer harboring a BRAF fusion (PMID: 31924734; NCT02465060).	31924734
BRAF fusion	high grade glioma	predicted - sensitive		Ulixertinib	Case Reports/Case Series	Actionable	In a Phase II trial (APEC1621J), Ulixertinib (BVD-523) treatment resulted in a 6-month progression-free survival rate of 37% but no objective response in pediatric and young adult patients with advanced solid tumors harboring MAPK pathway activation, however, a patient with high grade glioma harboring a BRAF fusion achieved prolonged stable disease and remained on treatment for 15 cycles (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 3009; NCT03698994).	detail...
BRAF fusion	low grade glioma	predicted - sensitive		Ulixertinib	Case Reports/Case Series	Actionable	In a Phase II trial (APEC1621J), Ulixertinib (BVD-523) treatment resulted in a 6-month progression-free survival rate of 37% but no objective response in pediatric and young adult patients with advanced solid tumors harboring MAPK pathway activation, however, a patient with low grade glioma harboring a BRAF fusion achieved prolonged stable disease and remained on treatment for 7 cycles (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 3009; NCT03698994).	detail...
BRAF fusion	Erdheim-Chester disease	predicted - sensitive		Cobimetinib	Case Reports/Case Series	Actionable	In a retrospective analysis, Cotellic (cobimetinib) treatment resulted in a partial response with a tumor reduction of 67% in a patient with Erdheim-Chester disease harboring a BRAF fusion, with the patient remaining on treatment for at least 22 months (PMID: 38922339; NCT01775072).	38922339
BRAF fusion	high grade glioma	predicted - sensitive		Selumetinib	Case Reports/Case Series	Actionable	In a retrospective analysis, Koselugo (selumetinib) treatment resulted in a partial response with a tumor reduction of 52% in a patient with high grade neuroepithelial tumor harboring a BRAF fusion (PMID: 38922339; NCT01775072).	38922339
BRAF fusion	Advanced Solid Tumor	predicted - sensitive		Binimetinib + Exarafenib	Case Reports/Case Series	Actionable	In a Phase I trial, treatment with the combination of Exarafenib (KIN-2787) and Mektovi (binimetinib) demonstrated safety in patients with NRAS-mutant melanoma (n=39) or other advanced solid tumors driven by BRAF class I or II alterations (n=10 and n=3) and resulted in one confirmed and one unconfirmed partial response in patients harboring BRAF fusions (n=3) (Ann Oncol (2024) 35 (Suppl_2): S491-S492; NCT04913285).	detail...
BRAF fusion	Advanced Solid Tumor	predicted - sensitive		DCC-3084	Preclinical - Cell culture	Actionable	In a preclinical study, DCC-3084 inhibited downstream signaling and proliferation in cells expressing a BRAF fusion in culture (Cancer Res (2023) 83 (7_Supplement): 4045).	detail...

Showing 1 to 14 of 14 entries

Filter rows: